Loading…

High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma

This study aimed to search for predictors of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) efficacy in previously treated patients with advanced squamous cell lung carcinoma in which EGFR mutations are very rare. EGFR gene copy numbers were assessed by FISH and evaluated a...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2012-03, Vol.18 (6), p.1760-1768
Main Authors: LEE, Youngjoo, HYO SUP SHIM, MOO SUK PARK, KIM, Joo-Hang, HA, Sang-Jun, SE HOON KIM, BYOUNG CHUL CHO
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c338t-be02b15240e5efca7da0721265618e129dae6d9bd3e2cf5f777d1318f598e0023
cites cdi_FETCH-LOGICAL-c338t-be02b15240e5efca7da0721265618e129dae6d9bd3e2cf5f777d1318f598e0023
container_end_page 1768
container_issue 6
container_start_page 1760
container_title Clinical cancer research
container_volume 18
creator LEE, Youngjoo
HYO SUP SHIM
MOO SUK PARK
KIM, Joo-Hang
HA, Sang-Jun
SE HOON KIM
BYOUNG CHUL CHO
description This study aimed to search for predictors of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) efficacy in previously treated patients with advanced squamous cell lung carcinoma in which EGFR mutations are very rare. EGFR gene copy numbers were assessed by FISH and evaluated as predictors of EGFR-TKI efficacy in 71 patients with advanced squamous cell lung cancer who received gefitinib or erlotinib as a second-line or higher therapy. The tumors were classified into EGFR/FISH-positive (high polysomy/gene amplification) and EGFR/FISH-negative (other) groups. EGFR/FISH was positive in 19 (26.7%) patients. Only EGFR/FISH positive status was correlated with the EGFR-TKIs response (EGFR/FISH(+) vs. EGFR/FISH(-), 26.3% vs. 2.0%; P = 0.005). In a multivariate analysis, the risk of progression was lower in EGFR/FISH-positive patients (HR of EGFR/FISH(+) vs. EGFR/FISH(-), 0.57; P = 0.057) or patients experiencing grade 2 or more rash (HR for rash grade 2 or more vs. less than 2, 0.54; P = 0.042), compared with EGFR/FISH-negative patients or those experiencing grade of less than 2 rash, respectively. When the combined criteria of EGFR/FISH and skin rash severity were analyzed, EGFR/FISH-negative patients with grade less than 2 rash had poorer clinical outcomes than patients with positive EGFR/FISH or grade 2 or more rash, apparent as a lower response rate (0.0% vs. 21.4%; P = 0.003) and a shorter median progression-free survival (1.13 months vs. 3.90 months; P = 0.0002). EGFR/FISH and skin rash severity may be used to identify which patients are likely to gain a benefit from EGFR-TKIs in this population.
doi_str_mv 10.1158/1078-0432.CCR-11-2582
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_928908702</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>928908702</sourcerecordid><originalsourceid>FETCH-LOGICAL-c338t-be02b15240e5efca7da0721265618e129dae6d9bd3e2cf5f777d1318f598e0023</originalsourceid><addsrcrecordid>eNpFkVFP2zAUha1paDDYT9jkl4mnMNupa-cRRVDQOkAde7Zu7Bvq0TjFTpj6U_i3uGvZnmxZ3zm-9xxCPnN2xrnU3zhTumCTUpzV9aLgvBBSi3fkiEupilJM5ft8f2MOyceUfjPGJ5xNPpBDIYTiWqkj8nLlH5b0Yna5oDMMSOt-vaE3Y9dgpBAc_fnoA11AWlJI9C6i83bwz0h_QHzEmGjbx536fhP75LPDdx8gIb0OS9_4oc9MdriDwWMYEv3jhyU9d88QLGb3pxG6fky0xtWKzsfwQGuI1oe-gxNy0MIq4af9eUx-XV7c11fF_HZ2XZ_PC1uWeigaZKLhUkwYSmwtKAdMCZ4DmHKNXFQOcOqqxpUobCtbpZTjJdetrDQyJspjcrrzXcf-acQ0mM4nm-eBgHk0UwldMa3-knJH2rxqitiadfQdxI3hzGxLMdvAzTZwk0vJT2ZbStZ92f8wNh26f6q3FjLwdQ9AsrBqY07Hp_-cVHmXKStfARjIlQ8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>928908702</pqid></control><display><type>article</type><title>High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma</title><source>Freely Accessible Journals</source><creator>LEE, Youngjoo ; HYO SUP SHIM ; MOO SUK PARK ; KIM, Joo-Hang ; HA, Sang-Jun ; SE HOON KIM ; BYOUNG CHUL CHO</creator><creatorcontrib>LEE, Youngjoo ; HYO SUP SHIM ; MOO SUK PARK ; KIM, Joo-Hang ; HA, Sang-Jun ; SE HOON KIM ; BYOUNG CHUL CHO</creatorcontrib><description>This study aimed to search for predictors of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) efficacy in previously treated patients with advanced squamous cell lung carcinoma in which EGFR mutations are very rare. EGFR gene copy numbers were assessed by FISH and evaluated as predictors of EGFR-TKI efficacy in 71 patients with advanced squamous cell lung cancer who received gefitinib or erlotinib as a second-line or higher therapy. The tumors were classified into EGFR/FISH-positive (high polysomy/gene amplification) and EGFR/FISH-negative (other) groups. EGFR/FISH was positive in 19 (26.7%) patients. Only EGFR/FISH positive status was correlated with the EGFR-TKIs response (EGFR/FISH(+) vs. EGFR/FISH(-), 26.3% vs. 2.0%; P = 0.005). In a multivariate analysis, the risk of progression was lower in EGFR/FISH-positive patients (HR of EGFR/FISH(+) vs. EGFR/FISH(-), 0.57; P = 0.057) or patients experiencing grade 2 or more rash (HR for rash grade 2 or more vs. less than 2, 0.54; P = 0.042), compared with EGFR/FISH-negative patients or those experiencing grade of less than 2 rash, respectively. When the combined criteria of EGFR/FISH and skin rash severity were analyzed, EGFR/FISH-negative patients with grade less than 2 rash had poorer clinical outcomes than patients with positive EGFR/FISH or grade 2 or more rash, apparent as a lower response rate (0.0% vs. 21.4%; P = 0.003) and a shorter median progression-free survival (1.13 months vs. 3.90 months; P = 0.0002). EGFR/FISH and skin rash severity may be used to identify which patients are likely to gain a benefit from EGFR-TKIs in this population.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-11-2582</identifier><identifier>PMID: 22271877</identifier><identifier>CODEN: CCREF4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Aged ; Antineoplastic agents ; Biological and medical sciences ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - genetics ; Carcinoma, Squamous Cell - mortality ; Dermatology ; Exanthema - complications ; Female ; Gene Dosage ; Genes, erbB-1 ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - mortality ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pneumology ; Protein Kinase Inhibitors - therapeutic use ; Receptor, Epidermal Growth Factor - antagonists &amp; inhibitors ; Retreatment ; Skin involvement in other diseases. Miscellaneous. General aspects ; Tumors of the respiratory system and mediastinum</subject><ispartof>Clinical cancer research, 2012-03, Vol.18 (6), p.1760-1768</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c338t-be02b15240e5efca7da0721265618e129dae6d9bd3e2cf5f777d1318f598e0023</citedby><cites>FETCH-LOGICAL-c338t-be02b15240e5efca7da0721265618e129dae6d9bd3e2cf5f777d1318f598e0023</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=25761860$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22271877$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LEE, Youngjoo</creatorcontrib><creatorcontrib>HYO SUP SHIM</creatorcontrib><creatorcontrib>MOO SUK PARK</creatorcontrib><creatorcontrib>KIM, Joo-Hang</creatorcontrib><creatorcontrib>HA, Sang-Jun</creatorcontrib><creatorcontrib>SE HOON KIM</creatorcontrib><creatorcontrib>BYOUNG CHUL CHO</creatorcontrib><title>High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>This study aimed to search for predictors of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) efficacy in previously treated patients with advanced squamous cell lung carcinoma in which EGFR mutations are very rare. EGFR gene copy numbers were assessed by FISH and evaluated as predictors of EGFR-TKI efficacy in 71 patients with advanced squamous cell lung cancer who received gefitinib or erlotinib as a second-line or higher therapy. The tumors were classified into EGFR/FISH-positive (high polysomy/gene amplification) and EGFR/FISH-negative (other) groups. EGFR/FISH was positive in 19 (26.7%) patients. Only EGFR/FISH positive status was correlated with the EGFR-TKIs response (EGFR/FISH(+) vs. EGFR/FISH(-), 26.3% vs. 2.0%; P = 0.005). In a multivariate analysis, the risk of progression was lower in EGFR/FISH-positive patients (HR of EGFR/FISH(+) vs. EGFR/FISH(-), 0.57; P = 0.057) or patients experiencing grade 2 or more rash (HR for rash grade 2 or more vs. less than 2, 0.54; P = 0.042), compared with EGFR/FISH-negative patients or those experiencing grade of less than 2 rash, respectively. When the combined criteria of EGFR/FISH and skin rash severity were analyzed, EGFR/FISH-negative patients with grade less than 2 rash had poorer clinical outcomes than patients with positive EGFR/FISH or grade 2 or more rash, apparent as a lower response rate (0.0% vs. 21.4%; P = 0.003) and a shorter median progression-free survival (1.13 months vs. 3.90 months; P = 0.0002). EGFR/FISH and skin rash severity may be used to identify which patients are likely to gain a benefit from EGFR-TKIs in this population.</description><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Carcinoma, Squamous Cell - genetics</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Dermatology</subject><subject>Exanthema - complications</subject><subject>Female</subject><subject>Gene Dosage</subject><subject>Genes, erbB-1</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - mortality</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Receptor, Epidermal Growth Factor - antagonists &amp; inhibitors</subject><subject>Retreatment</subject><subject>Skin involvement in other diseases. Miscellaneous. General aspects</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNpFkVFP2zAUha1paDDYT9jkl4mnMNupa-cRRVDQOkAde7Zu7Bvq0TjFTpj6U_i3uGvZnmxZ3zm-9xxCPnN2xrnU3zhTumCTUpzV9aLgvBBSi3fkiEupilJM5ft8f2MOyceUfjPGJ5xNPpBDIYTiWqkj8nLlH5b0Yna5oDMMSOt-vaE3Y9dgpBAc_fnoA11AWlJI9C6i83bwz0h_QHzEmGjbx536fhP75LPDdx8gIb0OS9_4oc9MdriDwWMYEv3jhyU9d88QLGb3pxG6fky0xtWKzsfwQGuI1oe-gxNy0MIq4af9eUx-XV7c11fF_HZ2XZ_PC1uWeigaZKLhUkwYSmwtKAdMCZ4DmHKNXFQOcOqqxpUobCtbpZTjJdetrDQyJspjcrrzXcf-acQ0mM4nm-eBgHk0UwldMa3-knJH2rxqitiadfQdxI3hzGxLMdvAzTZwk0vJT2ZbStZ92f8wNh26f6q3FjLwdQ9AsrBqY07Hp_-cVHmXKStfARjIlQ8</recordid><startdate>20120315</startdate><enddate>20120315</enddate><creator>LEE, Youngjoo</creator><creator>HYO SUP SHIM</creator><creator>MOO SUK PARK</creator><creator>KIM, Joo-Hang</creator><creator>HA, Sang-Jun</creator><creator>SE HOON KIM</creator><creator>BYOUNG CHUL CHO</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120315</creationdate><title>High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma</title><author>LEE, Youngjoo ; HYO SUP SHIM ; MOO SUK PARK ; KIM, Joo-Hang ; HA, Sang-Jun ; SE HOON KIM ; BYOUNG CHUL CHO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c338t-be02b15240e5efca7da0721265618e129dae6d9bd3e2cf5f777d1318f598e0023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Carcinoma, Squamous Cell - genetics</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Dermatology</topic><topic>Exanthema - complications</topic><topic>Female</topic><topic>Gene Dosage</topic><topic>Genes, erbB-1</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - mortality</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Receptor, Epidermal Growth Factor - antagonists &amp; inhibitors</topic><topic>Retreatment</topic><topic>Skin involvement in other diseases. Miscellaneous. General aspects</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LEE, Youngjoo</creatorcontrib><creatorcontrib>HYO SUP SHIM</creatorcontrib><creatorcontrib>MOO SUK PARK</creatorcontrib><creatorcontrib>KIM, Joo-Hang</creatorcontrib><creatorcontrib>HA, Sang-Jun</creatorcontrib><creatorcontrib>SE HOON KIM</creatorcontrib><creatorcontrib>BYOUNG CHUL CHO</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LEE, Youngjoo</au><au>HYO SUP SHIM</au><au>MOO SUK PARK</au><au>KIM, Joo-Hang</au><au>HA, Sang-Jun</au><au>SE HOON KIM</au><au>BYOUNG CHUL CHO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2012-03-15</date><risdate>2012</risdate><volume>18</volume><issue>6</issue><spage>1760</spage><epage>1768</epage><pages>1760-1768</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><coden>CCREF4</coden><abstract>This study aimed to search for predictors of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) efficacy in previously treated patients with advanced squamous cell lung carcinoma in which EGFR mutations are very rare. EGFR gene copy numbers were assessed by FISH and evaluated as predictors of EGFR-TKI efficacy in 71 patients with advanced squamous cell lung cancer who received gefitinib or erlotinib as a second-line or higher therapy. The tumors were classified into EGFR/FISH-positive (high polysomy/gene amplification) and EGFR/FISH-negative (other) groups. EGFR/FISH was positive in 19 (26.7%) patients. Only EGFR/FISH positive status was correlated with the EGFR-TKIs response (EGFR/FISH(+) vs. EGFR/FISH(-), 26.3% vs. 2.0%; P = 0.005). In a multivariate analysis, the risk of progression was lower in EGFR/FISH-positive patients (HR of EGFR/FISH(+) vs. EGFR/FISH(-), 0.57; P = 0.057) or patients experiencing grade 2 or more rash (HR for rash grade 2 or more vs. less than 2, 0.54; P = 0.042), compared with EGFR/FISH-negative patients or those experiencing grade of less than 2 rash, respectively. When the combined criteria of EGFR/FISH and skin rash severity were analyzed, EGFR/FISH-negative patients with grade less than 2 rash had poorer clinical outcomes than patients with positive EGFR/FISH or grade 2 or more rash, apparent as a lower response rate (0.0% vs. 21.4%; P = 0.003) and a shorter median progression-free survival (1.13 months vs. 3.90 months; P = 0.0002). EGFR/FISH and skin rash severity may be used to identify which patients are likely to gain a benefit from EGFR-TKIs in this population.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>22271877</pmid><doi>10.1158/1078-0432.CCR-11-2582</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 2012-03, Vol.18 (6), p.1760-1768
issn 1078-0432
1557-3265
language eng
recordid cdi_proquest_miscellaneous_928908702
source Freely Accessible Journals
subjects Aged
Antineoplastic agents
Biological and medical sciences
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - genetics
Carcinoma, Squamous Cell - mortality
Dermatology
Exanthema - complications
Female
Gene Dosage
Genes, erbB-1
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - mortality
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Pneumology
Protein Kinase Inhibitors - therapeutic use
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Retreatment
Skin involvement in other diseases. Miscellaneous. General aspects
Tumors of the respiratory system and mediastinum
title High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A36%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20EGFR%20Gene%20Copy%20Number%20and%20Skin%20Rash%20as%20Predictive%20Markers%20for%20EGFR%20Tyrosine%20Kinase%20Inhibitors%20in%20Patients%20with%20Advanced%20Squamous%20Cell%20Lung%20Carcinoma&rft.jtitle=Clinical%20cancer%20research&rft.au=LEE,%20Youngjoo&rft.date=2012-03-15&rft.volume=18&rft.issue=6&rft.spage=1760&rft.epage=1768&rft.pages=1760-1768&rft.issn=1078-0432&rft.eissn=1557-3265&rft.coden=CCREF4&rft_id=info:doi/10.1158/1078-0432.CCR-11-2582&rft_dat=%3Cproquest_cross%3E928908702%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c338t-be02b15240e5efca7da0721265618e129dae6d9bd3e2cf5f777d1318f598e0023%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=928908702&rft_id=info:pmid/22271877&rfr_iscdi=true